Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144690 · ClinicalTrials.gov registry record · Phase 2
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Phase 2 study of Epilepsy, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
NCT00144690 is a Phase 2 study of Epilepsy that has completed, run by Eisai. The trial reports 5 study locations across 5 states.
The verdict
NCT00144690, a Phase 2 study of Epilepsy, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
Study Summary
The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007 given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures (including secondarily generalized seizures). The secondary objectives are to evaluate the safety, efficacy, concentration-efficacy relationship, and pharmacokinetics of E2007 and the effects of E2007 on the Profile of Mood States (POMS) test.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG E2007 (perampanel)
Study Locations (5)
Arkansas
- Dept. of Neuro Surgery - Little Rock
Florida
- USF Physicians Group - Tampa
Michigan
- Clinical Trials - Detroit
Ohio
- Medical College of Ohio Comprehensive Epilepsy Ctr. - Toledo
Tennessee
- Vanderbilt University Medical Ctr. - Nashville
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144690
The ClinicalTrials.gov registry entry for NCT00144690 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00144690 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arkansas, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT00144690 about?
NCT00144690 is a clinical study titled "E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures". The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007 given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures (including secondarily generalized seizures). The secondary objectives are to evaluate the safety, efficacy, con...
What is the current status of trial NCT00144690?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-03. Estimated completion is 2007-02.
What conditions does trial NCT00144690 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00144690?
The interventions under investigation include: Placebo (DRUG), E2007 (perampanel) (DRUG).
Who is sponsoring clinical trial NCT00144690?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00144690 being conducted?
This trial has 5 study locations across Arkansas, Florida, Michigan, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.